Post Marketing Registry to Assess Usage, Safety and Effectiveness of Deltyba Tablets in Korean Patients With MDR-TB

Exclusion Criteria

• •1. Patients with known hypersensitivity to Delamanid or any excipients of Deltyba®
• •2. Patients whose serum albumin \< 2.8 g/dL
• •3. Patients taking medicinal products that are strong inducers of CYP3A (e.g. carbamazepine).
• •4. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.